Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EACR 2016 /
The changing process of drug discovery and design

9th - 12th Jul 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.07.16
Views: 1922
Rating:

Dr Ian Waddell - Cancer Research UK Manchester Institute, Manchester, UK

Dr Waddell speaks with ecancertv at EACR 2016 about changes in drug discovery.

With reference to his own research in PARG inhibitors, targeting therapies is described by Dr Waddell as an essential part of drug design, with biomarkers and patient selection are the forefront in trial design.

He also reports on Project Achilles from Dana Farber Cancer Institute.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation